# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:RAPT) with a Neutral.
Wolfe Research analyst Andy Chen downgrades RAPT Therapeutics (NASDAQ:RAPT) from Outperform to Peer Perform.
Barclays analyst Leon Wang downgrades RAPT Therapeutics (NASDAQ:RAPT) from Overweight to Equal-Weight and lowers the price t...
Guggenheim analyst Yatin Suneja downgrades RAPT Therapeutics (NASDAQ:RAPT) from Buy to Neutral.
RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to li...